IMMUTEP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.425 AUD | +3.66% |
|
-3.41% | +23.19% |
| Jun. 05 | Immutep Completes Stock Offering | MT |
| Jun. 03 | Immutep, Merck Collaborate on Trial for Lung Cancer Therapy | MT |
| Sales 2024 * | 3.55M 2.36M | Sales 2025 * | 14.85M 9.86M | Capitalization | 487M 324M |
|---|---|---|---|---|---|
| Net income 2024 * | -46M -30.54M | Net income 2025 * | -44M -29.22M | EV / Sales 2024 * | 105 x |
| Net cash position 2024 * | 116M 76.7M | Net cash position 2025 * | 85.07M 56.49M | EV / Sales 2025 * | 27.1 x |
| P/E ratio 2024 * |
-10.7
x | P/E ratio 2025 * |
-12.8
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.53% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +3.66% | ||
| 1 week | -3.41% | ||
| Current month | -5.56% | ||
| 1 month | -9.57% | ||
| 3 months | +14.86% | ||
| 6 months | +37.10% | ||
| Current year | +23.19% |
1 week
0.40
0.46
1 month
0.400.49
Current year
0.330.49
1 year
0.260.49
3 years
0.230.71
5 years
0.100.73
10 years
0.101.90
| Managers | Title | Age | Since |
|---|---|---|---|
Marc Voigt
CEO | Chief Executive Officer | 51 | 10-12-31 |
David Fang
DFI | Director of Finance/CFO | - | 18-02-28 |
Florian Vogl
CTO | Chief Tech/Sci/R&D Officer | - | 23-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Russell Howard
CHM | Chairman | 74 | 13-05-07 |
Marc Voigt
CEO | Chief Executive Officer | 51 | 10-12-31 |
Anne Anderson
BRD | Director/Board Member | - | Feb. 13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-06 | 0.425 | +3.66% | 8 357 768 |
| 24-06-05 | 0.41 | -8.89% | 16,805,920 |
| 24-05-31 | 0.45 | +2.27% | 2,195,050 |
| 24-05-30 | 0.44 | 0.00% | 2,081,315 |
| 24-05-29 | 0.44 | 0.00% | 418,498 |
Delayed Quote Australian S.E., June 06, 2024 at 02:10 am EDT
More quotes
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3âs ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
Calendar
2024-08-27
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.41
AUD
Average target price
0.944
AUD
Spread / Average Target
+130.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +23.19% | 324M | |
| +55.70% | 59.34B | |
| +42.49% | 40.24B | |
| -5.39% | 39.88B | |
| -5.56% | 28.55B | |
| +16.46% | 27.26B | |
| -20.56% | 19.23B | |
| +33.03% | 12.61B | |
| +2.72% | 12.49B | |
| +25.85% | 12.28B |
- Stock Market
- Equities
- IMM Stock
